Palisade Bio Announces Participation in Two Upcoming Investor Conferences
MWN-AI** Summary
Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company focused on developing innovative oral medications targeting inflammatory and fibrotic diseases, announced its participation in two investor conferences scheduled for March 2026. The first event is the TD Cowen 46th Annual Health Care Conference, taking place on March 2 in Boston, where Palisade management will present and hold one-on-one meetings with investors. The second event, the Leerink Partners 2026 Global Healthcare Conference, runs from March 8-11 in Miami, featuring similar one-on-one meeting opportunities.
Palisade Bio is advancing its lead program, PALI-2108, a once-daily oral PDE4 inhibitor prodrug aimed at selectively targeting the terminal ileum and colon. This innovative approach seeks to enhance pharmacology and patient tolerability while maintaining systemic control of the drug. In a recent Phase 1b trial, PALI-2108 demonstrated a remarkable 100% clinical response rate in the ulcerative colitis (UC) cohort, alongside favorable tolerability and localized activation within the gastrointestinal tract. The company is now preparing for a Phase 2 clinical study focused on evaluating clinical remission and other key biomarkers over a 12-week period, followed by an extension phase to assess remission maintenance, while also exploring its potential in treating fibrostenotic Crohn's disease.
Palisade Bio's commitment to precision pharmacology and differentiated drug delivery aims to significantly improve therapeutic outcomes for patients suffering from chronic inflammatory conditions. However, the company cautions investors that forward-looking statements regarding clinical trials and outcomes carry inherent risks and may differ from actual results. For more information, please visit their website at www.palisadebio.com.
MWN-AI** Analysis
Palisade Bio, Inc. (NASDAQ: PALI) stands at an intriguing juncture as it approaches two significant investor conferences in March 2026. The company is poised to share insights about its lead drug, PALI-2108, a next-gen PDE4 inhibitor designed for targeted treatment of inflammatory bowel diseases, including ulcerative colitis (UC) and fibrostenotic Crohn's disease. Given the promising Phase 1b trial results, which reported a 100% clinical response and no serious adverse events in the UC cohort, investor interest is likely to intensify.
As Palisade prepares for the TD Cowen 46th Annual Health Care Conference and the Leerink Partners 2026 Global Healthcare Conference, attention should be paid to not only the details of these presentations but also management's strategic vision for the Phase 2 clinical trials. The upcoming trials will assess clinical remission, response rates, and pharmacodynamic biomarkers, critical indicators that could influence investor confidence and stock valuation.
It’s important to recognize the potential catalysts that upcoming conference presentations could serve as. Positive investor reception and increased visibility may bolster Palisade's market positioning, especially if discussions focus on the drug's differentiation and clinical profile. Furthermore, while the initial results are encouraging, investors should remain cautious, given the inherent risks associated with clinical-stage biopharma—such as the possibility of future trial results diverging from prior successes or regulatory hurdles.
For current and prospective investors, a close eye on stock performance post-conferences will be crucial. Should the company deliver compelling narratives and achieve favorable conference outcomes, it might be wise to consider Palisade Bio as an intriguing addition to a well-diversified portfolio in the biopharmaceutical sector. However, thorough due diligence is recommended given the volatility inherent in biotech investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that management will participate in two upcoming investor conferences taking place during March 2026. Details are as follows:
TD Cowen 46th Annual Health Care Conference
Date/time: March 2, 2026 at 3:10 PM EST
Location: Boston Mariott Copley Place, Boston, MA
Format: In-person presentation & investor meetings
Webcast link: Register here
Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the TD Cowen one-on-one desk to request a meeting.
Leerink Partners 2026 Global Healthcare Conference
Date: March 8-11, 2026
Location: W South Beach, Miami, FL
Format: One-on-one investor meetings
Investors registered to attend the conference who wish to meet with Palisade Bio management should contact the Leerink one-on-one desk to request a meeting.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.
Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in fibrostenotic crohn’s disease to further characterize PALI-2108’s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ**
How is Palisade Bio Inc. (PALI) planning to differentiate its PDE4 inhibitor prodrugs in the competitive landscape of inflammatory disease treatments?
What specific outcomes is Palisade Bio Inc. (PALI) aiming to achieve with the upcoming Phase 2 clinical study for PALI-2108 in ulcerative colitis?
Can you elaborate on the pharmacokinetics of PALI-2108 and how they support its targeted delivery in clinical applications, specifically for Palisade Bio Inc. (PALI)?
What are the key risks identified by Palisade Bio Inc. (PALI) that could impact the timelines and success of its clinical trials for PALI-2108?
**MWN-AI FAQ is based on asking OpenAI questions about Palisade Bio Inc. (NASDAQ: PALI).
NASDAQ: PALI
PALI Trading
8.55% G/L:
$1.84 Last:
769,741 Volume:
$1.74 Open:
